BIOA Stock Summary and Trading Ideas (Bioage Labs | NASDAQ:BIOA)

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

Bioage Labs trades on the NASDAQ stock market under the symbol BIOA.

As of November 5, 2026, BIOA stock price declined to $5.50 with 333,888 million shares trading.

BIOA has a beta of 1.84, meaning it tends to be more sensitive to market movements. BIOA has a correlation of 0.03 to the broad based SPY ETF.

BIOA has a market cap of $252.43 million. This is considered a Small Cap stock.

Last quarter Bioage Labs reported $2 million in Revenue and -$.58 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.06.

The top ETF exchange traded funds that BIOA belongs to (by Net Assets): VTI, IWM, VXF, XPH, IWN.

BIOA has underperformed the market in the last year with a return of -26.4%, while the SPY ETF gained +10.1%. In the last 3 month period, BIOA fell short of the market, returning -50.9%, while SPY returned -4.4%. However, in the most recent 2 weeks BIOA has outperformed the stock market by returning -0.2%, while SPY returned -4.8%.

BIOA support price is $5.60 and resistance is $6.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIOA shares will trade within this expected range on the day.